Shrishti Saxena

Also affiliated with Harvard University, Center for Neuro-Oncology

MedicineBiochemistry, Genetics and Molecular BiologyNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis”.

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis

Neurology Neuroimmunology & Neuroinflammation(2022)10.1212/nxi.0000000000200052

N/A

0.773DataRank · unranked

172 citations

Brian C. Healy, Yanqing Liu, Shrishti Saxena, Anu Paul, Mariann Polgar‐Turcsanyi +6 more

Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis

Nature Communications(2024)10.1038/s41467-024-48602-9

N/A

0.529DataRank · unranked

33 citations

Ferhan Qureshi, Victor M. Gehman, Michael J. Becich, Riley Bove, Bruce Cree +14 more

Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study

Journal of Neuroinflammation(2023)10.1186/s12974-023-02816-8

N/A

0.425DataRank · unranked

16 citations

Gauruv Bose, Hrishikesh Lokhande, Shrishti Saxena, Brian C. Healy, Mariann Polgar‐Turcsanyi +3 more

miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod

Journal of Neuroinflammation(2023)10.1186/s12974-023-02811-z

N/A

0DataRank · unranked

9 citations

Rohit Patel, Brian C. Healy, Hrishikesh Lokhande, Anu Paul, Shrishti Saxena +4 more

Clinical Validation of a Multi-protein, Serum-based Assay for Disease Activity Assessments in Multiple Sclerosis

medRxiv(2023)10.1101/2023.02.08.23285438

N/A

0DataRank · unranked

2 citations

John Foley, Carolina Ionete, Nabil K. El Ayoubi, Shrishti Saxena, Patricia Gaitan-Walsh +15 more

MicroRNA-146a limits tumorigenic inflammation in colorectal cancer

Nature Communications(2021)10.1038/s41467-021-22641-y

N/A

0DataRank · unranked

130 citations

Amrendra K. Ajay, Mai Fujiwara, Galina Gabriely, Radhika Raheja, Chantal Kuhn +6 more

FABP7 is increased in progressive multiple sclerosis and induces a pro-inflammatory phenotype in monocytes through a glycolytic switch

Nature Communications(2025)10.1038/s41467-025-60747-9

N/A

0DataRank · unranked

4 citations

D. A. King, Brenna A. LaBarre, Hrishikesh Lokhande, Danielle Caefer, Johnna F. Varghese +7 more

microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance

Journal of Clinical Investigation(2022)10.1172/jci155693

N/A

0DataRank · unranked

45 citations

Radhika Raheja, Lucien P. Garo, Amrendra K. Ajay, Ryoko Kadowaki-Saga, Sukrut H. Karandikar +13 more

Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity

Neurology Neuroimmunology & Neuroinflammation(2023)10.1212/nxi.0000000000200167

N/A

0DataRank · unranked

25 citations

Brian C. Healy, Shrishti Saxena, Fermisk Saleh, Bonnie I. Glanz, Rohit Bakshi +3 more